Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Reconsiders Legal Strategy: Will Settlements Ease Vioxx Pain?

Executive Summary

Merck may opt to settle select Vioxx liability lawsuits in cases where the evidence is clearly in favor of the plaintiff in the wake of the Texas jury verdict against the drug maker

You may also be interested in...



Merck Vioxx Pain Subsides

An Atlantic City, N.J. state court jury verdict clears Merck of allegations the drug maker failed to properly warn patients of risks associated with the use of Vioxx (rofecoxib). "We presented a case that was solidly based on scientific evidence," Merck said. The case, Humeston v. Merck, is the second Vioxx case to reach trial; an Angleton, Texas jury found Merck liable for the death of Robert Ernst in August, awarding his widow $253.5 mil. in damages (1"The Pink Sheet" Aug. 29, 2005, p. 3)...

Merck Vioxx Pain Subsides

An Atlantic City, N.J. state court jury verdict clears Merck of allegations the drug maker failed to properly warn patients of risks associated with the use of Vioxx (rofecoxib). "We presented a case that was solidly based on scientific evidence," Merck said. The case, Humeston v. Merck, is the second Vioxx case to reach trial; an Angleton, Texas jury found Merck liable for the death of Robert Ernst in August, awarding his widow $253.5 mil. in damages (1"The Pink Sheet" Aug. 29, 2005, p. 3)...

Generics Infringe On Branded Stock Growth As Investors Eye Mergers, Part D

Generic drug consolidation and the pending implementation of Medicare Part D in January, with its cost pressures likely to benefit unbranded drugs, appear to be swaying investor confidence in favor of generic drug makers

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel